Which brings us to the problem we have commented on before: Infectious Disease docs do NOT want to give antibiotics to COVID patients unless they have to. With B there is no choice- lots of antibacterial activity and gram + more so than -. Yes Staph (incl MRSA)and Strep readily killed by B- that is why it is a great skin/cellulitis/ascess drug.
Reluctance to give antibiotics will matter not aat all if B beats C and it will be a monster drug. As previous stated(I am repetitive) if it works DeGrado is Person of the Year and Brilacidin is one of the world's great inventions.
It remains to be seen and in the meantime CNN tells me that Lousiana hospitalizations are up up and away. Not to mention the rest of the world.
Recall the tiresome Leo PRs- big market for Prurisol, big market for B OM.
Here is a real market opportunity- a pandemic with a slew of variants.
Can the FDA really not have had a peek at the data? Despite what Leo says?
How do they let the world burn and not get a sense of a potential IP cure a bit early? Since this wait is pointless?
News 
Market Data 
Discover 
AI
